FAP-α (Fibroblast activation protein-α) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway

BMC Cell Biology

Volumn 15, Issue 1, 2014, Pages

  Jia, Jun ^a,b   Martin, Tracey A ^a   Ye, Lin ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Breast Cancer; FAK; FAP ; Growth; Migration

Indexed keywords

ACTIN RELATED PROTEIN 2-3 COMPLEX; ACTIN RELATED PROTEIN 2-3 COMPLEX INHIBITOR; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEURAL WISKOTT ALDRICH SYNDROME PROTEIN; NEURAL WISKOTT ALDRICH SYNDROME PROTEIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLIPASE C GAMMA; PHOSPHOLIPASE C GAMMA INHIBITOR; PROTEIN INHIBITOR; RHO KINASE INHIBITOR; SEPRASE; UNCLASSIFIED DRUG; GELATINASE; MEMBRANE PROTEIN; SERINE PROTEINASE;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; BREAST; BREAST TUMOR; CELL MOTION; FEMALE; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GELATINASES; HUMANS; MCF-7 CELLS; MEMBRANE PROTEINS; PHOSPHORYLATION; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION;

EID: 84902553763     PISSN: None     EISSN: 14712121     Source Type: Journal    
DOI: 10.1186/1471-2121-15-16     Document Type: Article

References (40)

1. Chen WT, Kelly T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev 2003, 22(2-3):259-269.
2. Rosenblum JS, Kozarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 2003, 7(4):496-504. 10.1016/S1367-5931(03)00084-X, 12941425.
3. Ariga N, Sato E, Ohuchi N, Nagura H, Ohtani H. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer 2001, 95(1):67-72. 10.1002/1097-0215(20010120)95:1<67::AID-IJC1012>3.0.CO;2-U, 11241314.
4. Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007, 13(6):1736-1741. 10.1158/1078-0432.CCR-06-1746, 17363526.
5. Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM, Cheng JD. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 2008, 37(2):154-158. 10.1097/MPA.0b013e31816618ce, 18665076.
6. Goscinski MA, Suo Z, Florenes VA, Vlatkovic L, Nesland JM, Giecksky KE. FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions. Ultrastruct Pathol 2008, 32(3):89-96. 10.1080/01913120802034934, 18570153.
7. Kelly T, Kechelava S, Rozypal TL, West KW, Korourian S. Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers. Mod Pathol 1998, 11(9):855-863.
8. Okada K, Chen WT, Iwasa S, Jin X, Yamane T, Ooi A, Mitsumata M. Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer. Oncology 2003, 65(4):363-370. 10.1159/000074650, 14707457.
9. Jin X, Iwasa S, Okada K, Mitsumata M, Ooi A. Expression patterns of seprase, a membrane serine protease, in cervical carcinoma and cervical intraepithelial neoplasm. Anticancer Res 2003, 23(4):3195-3198.
10. Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, Itoh E, Kokubun S. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histopathology 2009, 55(4):432-440. 10.1111/j.1365-2559.2009.03399.x, 2784039, 19817894.
11. Mentlein R, Hattermann K, Hemion C, Jungbluth AA, Held-Feindt J. Expression and role of the cell surface protease seprase/fibroblast activation protein-alpha (FAP-alpha) in astroglial tumours. Biol Chem 2011, 392(3):199-207.
12. Ramirez-Montagut T, Blachere NE, Sviderskaya EV, Bennett DC, Rettig WJ, Garin-Chesa P, Houghton AN. FAPalpha, a surface peptidase expressed during wound healing, is a tumour suppressor. Oncogene 2004, 23(32):5435-5446. 10.1038/sj.onc.1207730, 15133496.
13. Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumour suppression of human non small cell lung carcinoma cells. Int J Cancer 2004, 109(6):855-866. 10.1002/ijc.20091, 15027119.
14. Goodman JD, Rozypal TL, Kelly T. Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin Exp Metastasis 2003, 20(5):459-470. 10.1023/A:1025493605850, 14524536.
15. Huang YS, Wang S, Kelly T. Seprase promotes rapid tumour growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res 2004, 64(8):2712-2716. 10.1158/0008-5472.CAN-03-3184, 15087384.
16. Cheng JD, Dunbracj RL, Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumour growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 2002, 62(16):4767-4772.
17. Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM. Abrogation of fibroblast activation protein enzymatic activity attenuates tumour growth. Mol Cancer Ther 2005, 4(3):351-360.
18. Huang Y, Simms AE, Mazur A, Wang S, Leon NR, Jones B, Aziz N, Kelly T. Fibroblast activation protein-alpha promotes tumour growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 2011, 28(6):567-579. 10.1007/s10585-011-9392-x, 21604185.
19. Wang XM, Yu DM, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 2005, 42(4):935-945. 10.1002/hep.20853, 16175601.
20. Martin TA, Harrison GM, Watkins G, Jiang WG. Claudin-16 reduces the aggressive behavior of human breast cancer cells. J Cell Biochem 2008, 05(1):41-52.
21. Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, Karl J. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res 2010, 16(24):6111-6121. 10.1158/1078-0432.CCR-10-0119, 20798228.
22. Wen Y, Wang CT, Ma TT, Li ZY, Zhou LN, Mu B, Leng F, Shi HS, LI YO, Wei YQ. Immunotherapy targeting fibroblast activation protein inhibits tumour growth and increases survival in a murine colon cancer model. Cancer Sci 2010, 101(11):2325-2332. 10.1111/j.1349-7006.2010.01695.x, 20804499.
23. Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, Kerjaschki D, Retting WJ, Adolf GR. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumour fibroblasts. Clin Cancer Res 2008, 14(14):4584-4592. 10.1158/1078-0432.CCR-07-5211, 18628473.
24. Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen V, McKee PA, Egleston B, Cohen SJ, Weiner LM, Meropol NJ, Cheng JD. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther 2007, 6(11):1691-1699. 10.4161/cbt.6.11.4874, 18032930.
25. O'Brien P, O'Connor BF. Seprase: an overview of an important matrix serine protease. Biochim Biophys Acta 2008, 1784(9):1130-1145. 10.1016/j.bbapap.2008.01.006, 18262497.
26. Niedermeyer J, Scanlan MJ, Garin-Chesa P, Daiber C, Fiebig HH, Old LJ, Rettig WJ, Schnapp A. Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int J Cancer 1997, 71(3):383-389. 10.1002/(SICI)1097-0215(19970502)71:3<383::AID-IJC14>3.0.CO;2-H, 9139873.
27. Goldstein LA, Chen WT. Identification of an alternatively spliced seprase mRNA that encodes a novel intracellular isoform. J Biol Chem 2000, 275(4):2554-2559. 10.1074/jbc.275.4.2554, 10644713.
28. Chen D, Kennedy A, Wang JY, Zeng W, Zhao Q, Pearl M, Zhang M, Suo Z, Nesland JM, Qiao Y, Ng AK, Hirashima N, Yamane T, Mori Y, Mitsumata M, Ghersi G, Chen WT. Activation of EDTA-resistant gelatinases in malignant human tumours. Cancer Res 2006, 66(20):9977-9985. 10.1158/0008-5472.CAN-06-1499, 1626657, 17047060.
29. Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang CS, Das M, Save V, Novelli M, Balkwill F, Fitzgerald RC. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A 2010, 107(5):2177-2182. 10.1073/pnas.0909797107, 2836667, 20080664.
30. White DE, Muller WJ. Multifaceted roles of integrins in breast cancer metastasis. J Mammary Gland Biol Neoplasia 2007, 12(2-3):135-142.
31. Luo M, Guan JL. Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett 2010, 289(2):127-139. 10.1016/j.canlet.2009.07.005, 2854647, 19643531.
32. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003, 116(Pt 8):1409-1416.
33. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomuara S, Fujimoto J, Okada M, Yamamoto T. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995, 377(6549):539-544. 10.1038/377539a0, 7566154.
34. Schlaepfer DD, Mitra SK. Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 2004, 14(1):92-101. 10.1016/j.gde.2003.12.002, 15108811.
35. Thamilselvan V, Craig DH, Basson MD. FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J 2007, 21(8):1730-1741. 10.1096/fj.06-6545com, 17317726.
36. Santos AM, Jung J, Aziz N, Kissil KL, Puré E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 2009, 119(12):3613-3625. 10.1172/JCI38988, 2786791, 19920354.
37. Dolznig H, Schweifer N, Puri C, Kraut N, Rettig WJ, Kerjaschki D, Garin-Chesa P. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun 2005, 5:10.
38. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330:827-830. 10.1126/science.1195300, 21051638.
39. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007, 7:800-808. 10.1038/nrc2228, 17851543.
40. Walsh MP, Duncan B, Larabee S, Krauss A, Davis JPE, Cui Y, Kim SY, Guimond M, Bachovchin M, Fry TJL. BoroPro Accelerates T Cell Priming via Modulation of Dendritic Cell Trafficking Resulting in Complete Regression of Established Murine. Tumors PLoS ONE 2013, 8(3):e58860.